866-997-4948(US-Canada Toll Free)

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Jan 2014

Category :

Metabolic Disorders

No. of Pages : 67 Pages


Global Markets Directs, \'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Review, H1 2014\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview 6
Therapeutics Development 7
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Overview 7
Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Development by Companies 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Investigation by Universities/Institutes 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Development by Companies 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Investigation by Universities/Institutes 16
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Companies Involved in Therapeutics Development 17
Merck & Co., Inc. 17
ReGenX Biosciences, LLC 18
Cerenis Therapeutics SA 19
Amgen Astellas BioPharma K.K. 20
Biospherics.net Incorporated 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Assessment by Therapeutic Class 31
Drug Profiles 33
anacetrapib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
evolocumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CER-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gene Therapy To Activate LDL Receptor For Familial Hypercholesterolemia - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antisense Oilgonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
BSN-272 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Recent Pipeline Updates 42
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects 49
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products 50
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Product Development Milestones 51
Featured News & Press Releases 51
Jan 28, 2014: Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol 51
Jan 23, 2014: Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol 53
Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 54
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 55
Nov 19, 2013: Amgen Announces Evolocumab Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol 57
Nov 12, 2013: Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013 59
Dec 13, 2012: CHMP Turns Down Genzyme\'s Kynamro For Treatment Of Patients With Certain Forms Of Familial Hypercholesterolaemia 60
Nov 05, 2012: Amgen\'s AMG 145 Combination Therapy Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia 61
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody 62
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet 63

Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Table


Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H1 2014 7
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Merck & Co., Inc., H1 2014 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by ReGenX Biosciences, LLC, H1 2014 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Cerenis Therapeutics SA, H1 2014 19
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Biospherics.net Incorporated, H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 28
Number of Products by Stage and Molecule Type, H1 2014 30
Number of Products by Stage and Therapeutic Class, H1 2014 32
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H1 2014 42
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects, H1 2014 49
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products, H1 2014 50

List of Chart


Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H1 2014 7
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Top 10 Route of Administration, H1 2014 27
Number of Products by Stage and Top 10 Route of Administration, H1 2014 28
Number of Products by Top 10 Molecule Type, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30
Number of Products by Top 10 Therapeutic Class, H1 2014 31
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *